Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis | Zendy

Melanie D. Whittington | Zendy; R. Brett McQueen | Zendy; Daniel A. Ollendorf | Zendy; Richard H. Chapman | Zendy; Varun Kumar | Zendy; Patricia G. Synnott | Zendy; Foluso Agboola | Zendy; Jonathan D. Campbell | Zendy

Open Access

Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis

Author(s) -

Melanie D. Whittington,

R. Brett McQueen,

Daniel A. Ollendorf,

Richard H. Chapman,

Varun Kumar,

Patricia G. Synnott,

Foluso Agboola,

Jonathan D. Campbell

Publication year - 2018

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2019.25.1.080

Subject(s) - medicine , adalimumab , rheumatoid arthritis , adverse effect

Rheumatoid arthritis is associated with a societal burden greater than $39 billion annually. Novel treatments, known as targeted immune modulators (TIMs), are expensive but effective, producing improvements in response rates compared with conventional disease-modifying antirheumatic drugs (cDMARDs). Sarilumab, a TIM approved in 2017, shows superior improvements compared with cDMARDs and produced significantly greater likelihood of achieving response and improvement in the Health Assessment Questionnaire Disability Index than adalimumab monotherapy. Although sarilumab monotherapy has shown improvements over cDMARDs and the TIM market leader adalimumab, treatment with sarilumab is costly, with an annual wholesale acquisition cost of $39,000.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research